CAMBRIDGE, Mass. – July 1, 2019 –  Foundation Medicine, Inc. today announced it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic for LYNPARZA® (Olaparib) for first line maintenance therapy in BRCA-mutated advanced

Collaboration will start with development of a companion diagnostic for Vitrakvi ® (larotrectinib), the first and only TRK inhibitor approved in the U.S. for patients with TRK fusion cancer across all solid tumors; Vitrakvi is under review in other markets around the world Goal is to advance broad

CAMBRIDGE, Mass. – May 16, 2019 –  Foundation Medicine, Inc. today announced that new data informed by the use of its portfolio of comprehensive genomic profiling (CGP) tests will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31 to June

Journal of the American Medical Association Manuscript Supports the Value of Real-World Evidence as a Novel Method to Advance Research and Discovery CAMBRIDGE, Mass. & NEW YORK--( BUSINESS WIRE )--Foundation Medicine and Flatiron Health today announced the publication of study results in the

Veterans with Advanced Cancer to Have Better Access to Foundation Medicine’s Comprehensive Genomic Profiling Tests to Help Inform Personalized Treatment Plans   CAMBRIDGE, Mass. -- February 5, 2019 --  Foundation Medicine, Inc. today announced a nationwide contract with the U.S.

Proven biopharma executive leader, Cindy Perettie, named as chief executive officer to succeed Troy Cox   CAMBRIDGE, Mass. – January 7, 2019 – Foundation Medicine, Inc. today announced the appointment of Cindy Perettie as chief executive officer, effective February 4, 2019. Ms.

Breakthrough Approval Enables Patient Access to Comprehensive Genomic Profiling and Advances Oncology Therapy Development in Japan CAMBRIDGE, Mass.-- December 27, 2018 -- Foundation Medicine, Inc. today announced that Japan’s regulatory agency, the Ministry of Health, Labour and Welfare (MHLW) has

Novartis to Leverage Foundation Medicine’s Molecular Information Solutions to Develop Companion Diagnostics for Cancer Therapies CAMBRIDGE, Mass.-- October 17, 2018 -- Foundation Medicine, Inc. today announced a strategic collaboration with Novartis allowing the development of companion diagnostic

– FoundationOne Liquid analyzes 70 genes known to drive cancer growth and reports microsatellite instability high (MSI-high) status to inform the use of precision oncology treatments, including immunotherapies, with a simple blood draw – CAMBRIDGE, Mass.

-- New publication details Foundation Medicine’s assay’s ability to measure bTMB and to identify patients who may benefit from anti-PD-L1 therapy -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 6, 2018-- Foundation Medicine , today announced the publication of the results of a large study demonstrating